Name: KN-92 hydrochloride
Price: 413.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    KN-92 is an inactive analog of KN-93. KN-93 is the CaM kinase II inhibitor. [1] Hearts were treated with the CaM kinase inhibitor KN-93 or the inactive analog KN-92 (0.5 μM) for 10 min before clofilium exposure. Early afterdepolarizations (EADs) were largely inhibited by KN-93 contrasted to KN-92. There were little differences in parameters favoring EADs such as monophasic action potential duration or heart rate in KN-92- or KN-93- treated hearts. CaM kinase activity in situ increased 37% in hearts with EADs compared to hearts without EADs. This increase in CaM kinase activity was prevented by pretreatment with KN-93. [1] In vitro, KN-93 potently suppressed rabbit myocardial CaM kinase activity (calculated Ki ≤ 2.58 μM), but the inactive analog KN-92 did not (Ki > 100 μM). The actions of KN-93 and KN-92 on ICa and other repolarizing K+currents did not illustrate preferential EAD suppression by KN-93. [1]
    
    Reference:
    1. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J Pharmacol Exp Ther. 1998 Dec;287(3):996-1006.
- Properties
  - Categories
    
    Inactive derivative of KN-93, control compound
    
    Alternative Name
    
    KN 92 hydrochloride;KN92 hydrochloride; (E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-4-methoxybenzenesulfonamide hydrochloride
    
    CAS Number
    
    1431698-47-3
    
    Molecular Formula
    
    C24H26Cl2N2O3S
    
    Molecular Weight
    
    493.45
    
    Appearance
    
    A solid
    
    Purity
    
    98.42%
    
    Solubility
    
    ≥24.65 mg/mL in DMSO; insoluble in H2O; ≥11.73 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    ClC1=CC=C(/C=C/CN(C)CC2=CC=CC=C2NS(C3=CC=C(OC)C=C3)(=O)=O)C=C1.Cl
    
    * For Research Use Only
- Reference
  - 1. Christopher Veitch. "The α-Adrenergic System and CaMKII in Diabetic Heart Disease." University of Otago. 2019.